{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:08:10Z","timestamp":1789049290676,"version":"build-2803163510"},"reference-count":52,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babe\u0219 University of Medicine and Pharmacy Timi\u0219oara"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: General cardio-oncology guidance describes cardiovascular toxicity from BRAF\/MEK inhibitors and immune checkpoint inhibitors (ICIs), but it does not resolve how treatment decisions should change when heart failure (HF) is already present. This critical narrative review separates direct HF-specific evidence from indirect evidence and proposes an HF-centered framework for systemic melanoma. Methods: MEDLINE\/PubMed, Embase, and the Cochrane Library were searched for English-language sources published from January 2015 to April 2026, with targeted guideline, prescribing-information, interaction, and geriatric-oncology updates through July 2026. Sources were classified as direct, indirect, or extrapolated. This review follows SANRA principles but does not claim systematic-review conduct, pooled estimates, formal risk-of-bias assessment, or GRADE certainty. Results: Only case-level evidence directly describes systemic melanoma treatment in established HF; most cardiotoxicity rates are derived from selected longitudinal and real-world cohorts. We therefore organize decisions across four domains: HF phenotype and current stability; oncological urgency and alternatives; treatment-specific toxicity phenotype; and detectability, reversibility, and patient priorities. Each domain is graded ordinally and generates its own decision output, and explicit precedence rules resolve situations in which several domains are simultaneously abnormal; the pathway from assessment to documented output is presented as a decision flowchart and applied to illustrative clinical cases. This approach modifies interpretation of symptoms, biomarkers, ventricular function, surveillance, drug interactions, treatment interruption, and rechallenge. Every actionable statement is labeled as guideline-supported or author-proposed, therapy-specific baseline and follow-up monitoring are tabulated separately for each treatment class, and heart failure with preserved ejection fraction is addressed as a phenotype in which clinical deterioration may occur without any change in ejection fraction. Patient-level priorities in older adults\u2014survival, quality of life, avoidance of hospitalization, tolerance of frequent monitoring, oral versus infusion treatment, and functional expectation\u2014are specified as items to be recorded rather than inferred. Conclusions: Stable HF is not an automatic contraindication to effective melanoma therapy, whereas recent or active decompensation requires stabilization or monitored treatment when oncological delay is unsafe. The proposed framework operationalizes guideline principles for an understudied population while making the limits of the evidence explicit. It makes a procedural rather than an empirical claim: it is a transparent structure for documenting a decision that must be made anyway, not an algorithm derived from or validated against outcome data.<\/jats:p>","DOI":"10.3390\/jcm15187022","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:04:57Z","timestamp":1789045497000},"page":"7022","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Melanoma Therapy in Patients with Pre-Existing Heart Failure: An HF-Centered Decision Framework and Critical Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8837-1558","authenticated-orcid":false,"given":"Daniela-Vasilica","family":"Serban","sequence":"first","affiliation":[{"name":"Doctoral School, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4951-1702","authenticated-orcid":false,"given":"Diana-Maria","family":"Mateescu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Clinical Hospital CF Timi\u0219oara, 1 G\u0103rii Street, 300166 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"given":"Daniela","family":"Crainic","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2187-289X","authenticated-orcid":false,"given":"Nina","family":"Ivanovic","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-0809","authenticated-orcid":false,"given":"Roxana Manuela","family":"Fericean","sequence":"additional","affiliation":[{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-423X","authenticated-orcid":false,"given":"Florina Maria","family":"Bojin","sequence":"additional","affiliation":[{"name":"Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Research Center for Gene and Cellular Therapies in the Treatment of Cancer\u2014OncoGen, Timis County Emergency Clinical Hospital \u201cPius Brinzeu\u201d, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"Ana-Olivia","family":"Toma","sequence":"additional","affiliation":[{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Elena Daniela","family":"Jurj","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Center for Drug Data Analysis, Cheminformatics, and the Internet of Medical Things, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, Eftimie Murgu Square, No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Emilia","family":"Clej","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Virgil","family":"Paunescu","sequence":"additional","affiliation":[{"name":"Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Research Center for Gene and Cellular Therapies in the Treatment of Cancer\u2014OncoGen, Timis County Emergency Clinical Hospital \u201cPius Brinzeu\u201d, 300723 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jgo.2022.05.005","article-title":"Association of Age with Survival in Older Patients with Cutaneous Melanoma Treated with Immune Checkpoint Inhibitors","volume":"13","author":"Howell","year":"2022","journal-title":"J. Geriatr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A Scale for the Quality Assessment of Narrative Review Articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Nishizawa, A., Kawakami, M., and Kitahara, Y. (2024). Case Report: A Case of Metastatic BRAF V600-Mutated Melanoma with Heart Failure Treated with Immune Checkpoint Inhibitors and BRAF\/MEK Inhibitors. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1366532"},{"key":"ref_8","first-page":"e72313","article-title":"Cardiotoxicity of BRAF\/MEK Inhibitors Mimicking Apical Hypertrophic Cardiomyopathy","volume":"16","author":"Benko","year":"2024","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2340\/1651-226X.2025.42567","article-title":"Cardiotoxicity in Patients with Metastatic Melanoma Treated with BRAF\/MEK Inhibitors: A Real-World Analysis of Incidence, Risk Factors, and Reversibility","volume":"64","author":"Oddershede","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pedersen, S., Nielsen, M.\u00d8., Donia, M., Svane, I.M., Zerahn, B., and Ellebaek, E. (2024). Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib. Cancers, 16.","DOI":"10.3390\/cancers16172945"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Russo, G., Cicala, G., Zito, C., Spina, E., Silvestris, N., and Santarpia, M. (2025). Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data through a Retrospective Disproportionality Analysis, 2014\u20132023. Cancers, 17.","DOI":"10.3390\/cancers17111755"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaccao.2025.08.006","article-title":"Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients with Melanoma","volume":"7","author":"Glen","year":"2025","journal-title":"JACC CardioOncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity Associated with CTLA4 and PD1 Blocking Immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","first-page":"5","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis: A Review of Current State of Knowledge","volume":"5","author":"Wang","year":"2025","journal-title":"J. Cardiovasc. Aging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune Checkpoint Inhibitor-Induced Myositis, the Earliest and Most Lethal Complication among Rheumatic and Musculoskeletal Toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated with Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, C., Zhao, G., Zhang, Z., Yang, L., Liu, S., Li, G., Wang, H., Huang, J., Wang, S., and Li, N. (2023). Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Analysis of Case Reports. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1275254"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaccao.2024.07.002","article-title":"Steroids in Immune Checkpoint Inhibitor Myocarditis","volume":"6","author":"Palaskas","year":"2024","journal-title":"JACC CardioOncology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining Cardiovascular Toxicities of Cancer Therapies: An International Cardio-Oncology Society Consensus Statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Heart Failure Association in Collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/CMR.0000000000000997","article-title":"Real-World Evidence on Efficacy and Toxicity of Targeted Therapy in Older Melanoma Patients Treated in a Tertiary-Hospital Setting","volume":"34","author":"Stoff","year":"2024","journal-title":"Melanoma Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40266-024-01114-z","article-title":"Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study","volume":"41","author":"Trompet","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/S1470-2045(24)00404-2","article-title":"Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer: Recommendations from the International Society of Geriatric Oncology (SIOG)","volume":"26","author":"Neuendorff","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_30","unstructured":"National Library of Medicine (2026, July 31). DailyMed: TAFINLAR (Dabrafenib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea."},{"key":"ref_31","unstructured":"National Library of Medicine (2026, July 31). DailyMed: MEKINIST (Trametinib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1."},{"key":"ref_32","unstructured":"National Library of Medicine (2026, July 31). DailyMed: BRAFTOVI (Encorafenib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c."},{"key":"ref_33","unstructured":"National Library of Medicine (2026, July 31). DailyMed: MEKTOVI (Binimetinib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6c3408ac-d401-4925-8a03-26591afbc240."},{"key":"ref_34","unstructured":"National Library of Medicine (2026, July 31). DailyMed: ZELBORAF (Vemurafenib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=38eea320-7e0c-485a-bc30-98c3c45e2763."},{"key":"ref_35","unstructured":"National Library of Medicine (2026, July 31). DailyMed: COTELLIC (Cobimetinib)\u2014Full Prescribing Information, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c387579e-cee0-4334-bd1e-73f93ac1bde6."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial\u2014ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e70026","DOI":"10.1111\/pcmr.70026","article-title":"Impact of Drug\u2013Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated with Combined BRAF\/MEK Inhibitors: A Real-World Study","volume":"38","author":"Mezi","year":"2025","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mezi, S., Botticelli, A., Scagnoli, S., Pomati, G., Fiscon, G., De Galitiis, F., Di Pietro, F.R., Verkhovskaia, S., Amirhassankhani, S., and Pisegna, S. (2023). The Impact of Drug\u2013Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 15.","DOI":"10.3390\/cancers15184587"},{"key":"ref_40","unstructured":"University of Liverpool and Radboud University Medical Center (2026, July 31). Cancer Drug Interactions. Available online: https:\/\/cancer-druginteractions.org\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e029211","DOI":"10.1161\/JAHA.122.029211","article-title":"Diagnostic Value of the International Society of Cardio-Oncology Definition for Suspected Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"12","author":"Deharo","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/ehf2.14360","article-title":"Value of Troponin T versus I in the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis and Myositis: Rechallenge?","volume":"10","author":"Rossi","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40959-021-00095-x","article-title":"Treatment of Corticosteroid-Refractory Immune Checkpoint Inhibitor Myocarditis with Infliximab: A Case Series","volume":"7","author":"Zhang","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_47","unstructured":"U.S. Food and Drug Administration (2026, July 31). REMICADE (Infliximab)\u2014Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified Immunosuppressive Therapy in Patients with Immune Checkpoint Inhibitor-Induced Myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Manta, E., Iliakis, P., Fragoulis, C., Leontsinis, I., Stamoulopoulos, I., Chrysohoou, C., and Tsioufis, K. (2025). Tracking Pathways Linking Obesity with Heart Failure. Nutrients, 17.","DOI":"10.3390\/nu17071250"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:16:38Z","timestamp":1789046198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":52,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187022"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187022","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}